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Abstract  15	  
Biofilms formed by pathogenic bacteria and fungi are associated with a wide range of 16	  
diseases, from device-related infections (such as catheters or prosthetic joints) to chronic 17	  
infections occurring on native tissues (such as lung infections in cystic fibrosis patients). 18	  
Biofilms are therefore responsible for an important medical and economic burden. 19	  
Currently-used antibiotics have mostly been developed to target exponentially growing 20	  
microorganisms and are poorly effective against biofilms. In particular, even high 21	  
concentrations of bactericidal antibiotics are inactive against a subset of persistent biofilm 22	  
bacteria, which can cause infection recurrence despite prolonged treatments. While the 23	  
search for a magic bullet antibiotic effective against both planktonic and biofilm bacteria is 24	  
still active, alternative preventive and curative approaches are currently being developed 25	  
either limiting adhesion or biofilm formation or targeting biofilm tolerance by killing persister 26	  
bacteria. Most of these approaches are adjunctive using new molecules in combination 27	  
with antibiotics. This review presents promising approaches or strategies that could 28	  
improve our ability to prevent or eradicate bacterial biofilms in medical settings. 29	  
 30	  31	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 32	  
Highlights 33	  
• Currently-used antibiotics were developed to target planktonic bacteria 34	  
• Recent discoveries on biofilm properties led to promising anti-biofilm strategies  35	  
• Biofilm inhibition should integrate biocidal and non-biocidal approaches 36	  
• Jamming bacterial communication and regulation can prevent biofilm formation  37	  
• Major anti-biofilm approaches rely on matrix dissolution and potentiation of existing 38	  
antibiotics against persisters 39	  40	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Introduction 41	  
Since the first observation of a direct link between development of biofilm and persistent 42	  
infections [1-3], modern medicine is facing a double challenge: getting around the 43	  
increasing concern of multidrug antibiotic resistance and tackling sources of biofilm-related 44	  
infections. There is probably little hope to witness the rapid development of novel antibiotic 45	  
molecules that would not only overcome multidrug resistance but also be more efficient 46	  
than current antibiotics against medical biofilms. Indeed, most of the currently-used drugs 47	  
have been developed and optimized to kill planktonic microorganisms. 48	  
The identification of novel molecules designed to specifically target mechanisms involved 49	  
in biofilm formation or biofilm tolerance towards antibiotics could lead to novel therapies 50	  
specifically designed to be combined with antibiotics against bacterial biofilm-associated 51	  
infections. This review presents recent therapeutic approaches developed to specifically 52	  
target biofilm-associated bacterial infections. 53	  
 54	  55	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Strategies targeting specific mechanisms involved in biofilm 56	  
formation 57	  
 58	  
Anti-adhesion strategies 59	  
One of the crucial steps in biofilm development is the initial interaction of bacteria to abiotic 60	  
or biotic surfaces that can ultimately lead to colonization and infection by pathogenic 61	  
bacteria. Reducing adhesion is therefore a strategy of choice to prevent biofilm formation 62	  
and related infections. Among the different strategies recently developed to reduce 63	  
bacterial adhesion, one can distinguish strategies that non-specifically inhibit adhesion 64	  
versus strategies that are rather targeting specific adhesins (Figure). 65	  
 66	  
Non-specific inhibition of adhesion  67	  
Non-specific inhibition of adhesion is generally obtained by surface modification using 68	  
polymers. The type of polymers can be chosen on the basis of its anti-adhesive properties. 69	  
For example, Hook et al. assessed hundreds of polymeric materials using an high 70	  
throughput microarray assay for their anti-adhesive properties and identified materials 71	  
comprising ester and cyclic hydrocarbon moieties displaying anti-adhesive activity in vitro 72	  
against Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus, and in 73	  
vivo, against S. aureus, when grafted to silicone in a mice model of subcutaneously 74	  
implanted device [4]. An efficient anti-adhesive molecule should not only limit bacterial 75	  
proteins but also host proteins interaction to surfaces, therefore avoiding the formation of a 76	  
conditioning film subsequently favoring bacterial colonization. Such molecules, for instance 77	  
non-leaching polymeric sulfobetaine (polySB) that works as a wetting agent, have been 78	  
demonstrated to reduce protein, host cells and microbial adhesion, but also thrombus 79	  
formation in vitro and in vivo [5••]. More recently, a biomimetic strategy using a glycocalyx-80	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like molecule, methyl-cellulose, displaying anti-adhesive property for both cells and 81	  
bacteria, has been used to coat totally implanted venous access ports (TIVAP). Coated 82	  
TIVAP implanted in rats for several days displayed important resistance toward adhesion, 83	  
strongly reduced biofilm formation by P. aeruginosa and S. aureus as well as infective 84	  
thrombus [6••].  85	  
Beyond sole anti-adhesive strategies, surfaces combining different activities such as tissue 86	  
integration, biocide property and anti-adhesive activity are currently developed [7•-9•]. A 87	  
recent example of such a strategy displaying promising in vitro activity are anti-adhesive 88	  
polymer brushes composed of block copolymer Pluronic F-127 (PF127) functionalized with 89	  
antimicrobial peptides (AMP), able to kill bacteria on contact, and arginine− 90	  
glycine−aspartate (RGD) peptides promoting the adhesion and spread of host tissue cells 91	  
[10•]. 92	  
 93	  
Specific targeting of adhesins  94	  
Anti-biofilm approaches targeting specific adhesins have been shown to display strong 95	  
anti-adhesive and anti-infective potential. Some molecules can impede the biogenesis of 96	  
adhesins such as the one developed to block different fimbrial adhesins including the well-97	  
known type 1 fimbriae involved in bladder colonization by uropathogenic E. coli [11-14]. 98	  
Type 1 fimbriae have also been the target of sugar analogues competing with eukaryotic 99	  
receptors interacting with the tip-lectin, FimH. Among several molecules, some FimH 100	  
inhibitors have been shown in mice to successfully prevent catheter-associated urinary 101	  
tract infections by drug sensitive uropathogenic E. coli (UPEC) or to treat chronic cystitis in 102	  
mice infected by the multidrug-resistant UPEC clone ST131 [15••,16•]. Carbohydrate 103	  
inhibitors have also been developed against P. aeruginosa lectins, some of which 104	  
prevented lung colonization in mouse models [17,18]. Interestingly, anti-biofilm action was 105	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also achieved by using molecules combining several activities such as maltose derivatives 106	  
with bulky hydro-carbon groups that presented both a surfactant/biofilm dispersion activity 107	  
and an inhibition of adhesins/receptors mediated binding of P. aeruginosa [19•]. 108	  
 109	  
Targeting biofilm maturation 110	  
Biofilm-related infection can also be reduced by blocking the biofilm maturation process 111	  
(Figure). In most cases, strategies targeting biofilm maturation should also include 112	  
treatment with an antimicrobial for an in vivo use to avoid the release of a massive quantity 113	  
of biofilm bacteria into the bloodstream. 114	  
 115	  
Major signaling pathways as antibiofilm targets 116	  
Among the major mechanisms that are governing biofilm maturation are quorum-sensing 117	  
(QS) signals. We will not develop these aspects of anti-biofilm arsenal since several 118	  
excellent reviews were recently written on the various strategies used to interfer with 119	  
quorum-sensing including the use of analogues of homoserine lactones or AI-2 and 120	  
enzymes degrading QS molecules for Gram-negative bacteria, and auto-inducing peptides 121	  
or RNA-III inhibiting peptides for Gram-positive bacteria [20-22]. 122	  
Discovery of the importance of small messenger molecule c-di-GMP in the physiological 123	  
switch between planktonic to biofilm lifestyle is more recent and c-di-GMP is now 124	  
considered as a valuable target to fight biofilm-related infections. Screening of chemical 125	  
libraries led to the identification of direct or indirect inhibitors of diguanylate cyclases (the 126	  
enzymes producing c-di-GMP), reducing biofilm formation such as sulfathiazole or 127	  
azathioprine, an immunosuppressive drug [23-26]. Alternatively, a molecule impacting 128	  
biofilm formation produced by P. aeruginosa, nitric oxide (NO), has been demonstrated to 129	  
induce dispersal via the reduction of c-di-GMP concentrations through increased activity of 130	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phospho-diesterases (PDE) [27], demonstrating the potential of compounds naturally 131	  
produced by micro-organisms (see Table). In P. aeruginosa, NO-induced dispersal has 132	  
been recently linked to a specific PDE, NdbA, whose mRNA transcription is induced by NO 133	  
[28]. Interestingly, NO seems to be involved also in the dispersal of biofilms formed by 134	  
other micro-organisms, however through a different mechanism involving H-NOX proteins. 135	  
Therefore, development of surfaces releasing NO might be promising to control biofilm 136	  
formation as demonstrated by the use of NO donor-coated urinary catheters and 137	  
nanoparticles [29,30]. 138	  
 139	  
Direct action on matrix components to weaken biofilms 140	  
Two factors regulated by quorum-sensing and c-di-GMP play a major role in the 141	  
architecture of biofilms: polysaccharides and extracellular DNA [31-34]. Thus, direct 142	  
targeting of these factors instead of their signaling pathways can also be envisaged to 143	  
reduce biofilm formation. Strategies using enzymatic degradation of these matrix 144	  
components such as the use of DNaseI or Dispersin B, an hexosaminidase naturally 145	  
produced by Aggregatibacter actinomycetemcomitans and hydrolyzing poly-N-146	  
acetylglucosamine (a frequent component of E. coli, S. aureus or Staphylococcus 147	  
epidermidis exopolysaccharides), have been identified as efficient ways to disperse 148	  
biofilms in vitro and in vivo (see for example, [35-37]). However, enzyme-based 149	  
approaches are associated with two limitations: i) their restricted spectrum of action; and ii) 150	  
the risk of immunization against these molecules. The association of chelators of divalent 151	  
cations such as citrate or EDTA and biocides has also been proposed, based on their 152	  
ability to destabilize biofilm matrix [38,39]. These chelators could find their interest in the 153	  
case of local infection or restricted colonization such as device-related infection and have 154	  
been used as preventive agents in clinical trials [40]. Additionally, EDTA was proven an 155	  
efficient adjuvant to gentamicin to eradicate E. coli, P. aeruginosa S. aureus and S. 156	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epidermidis biofilms including persister cells (see below) in a rat model of catheter-related 157	  
infection [41•]. 158	  
 159	  
Strategies targeting mechanisms governing biofilm tolerance 160	  
towards antibiotics: fighting persisters 161	  
 162	  
One major problem caused by biofilms is their increased tolerance towards antimicrobial 163	  
agents that impairs the treatment of biofilm-related infections in clinical settings [42]. While 164	  
increased tolerance of biofilms is multifactorial, the main mechanism currently proposed to 165	  
explain such tolerance is the presence of persisters, bacteria that enter in a specific 166	  
phenotype state allowing them to survive in the presence of 1000 fold the minimum 167	  
inhibitory concentration of bactericidal antibiotics [43,44]. Persister cells have recently 168	  
been subjected to an intense hunt in order to limit biofilm-associated antibiotic tolerance. 169	  
 170	  
Reducing persisters formation 171	  
There are now growing evidences that one of the main factors leading to persisters 172	  
formation is nutritional stress, with a major effector molecule, ppGpp, the mediator of 173	  
stringent response ([45], for a comprehensive review see [46••]). Regarding the central role 174	  
for ppGpp in persistence, it is tempting to hypothesize that strategies leading to reduced 175	  
level of ppGpp could help fighting persisters. Relacin, a synthetic ppGpp analog inhibiting 176	  
the Bacillus subtilis RelA synthetase activity and biofilm formation [47], and relacin 177	  
derivatives displayed an inhibitory activity against different Rel proteins [48]. These 178	  
different compounds still need to be assessed for their capacity to reduce persisters 179	  
formation. Another stringent response inhibitor has been identified, the peptide 1018 180	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(VRLIVAV- RIWRR-NH2). While a direct evidence of its activity on persister cells is 181	  
missing, this peptide displayed a specific antibiofilm activity against in vitro biofilms formed 182	  
by several species including P. aeruginosa or S. aureus by inducing ppGpp degradation 183	  
[49••] and a synergistic action together with ciprofloxacin on in vitro biofilms of various 184	  
pathogens [50•]. Interestingly, this latter study demonstrates how adjuvant therapies can 185	  
allow reducing the concentration of antibiotic required to inhibit biofilm formation. 186	  
 187	  
Killing persisters 188	  
Once a biofilm is mature, the last resort option for biofilm eradication is to identify 189	  
compound that would increase antibiotic activity against persisters (Figure). Silver has 190	  
been shown to potentiate the activity of several antibiotics against biofilm and persisters of 191	  
Gram-negative and Gram-positive bacteria in a mouse biofilm model with subcutaneous 192	  
catheter by increasing ROS production and bacterial permeability to antibiotics [51••]. 193	  
Sugar metabolism was also used to obtain antibiotic potentiation against persisters 194	  
through an increased aminoglycosides penetration powered by the proton motive force 195	  
[52,53]. Alcalinisation by basic amino-acids such as L-arginine was also recently 196	  
demonstrated to enhance aminoglycoside action in vitro and in vivo against biofilms and 197	  
persisters [54•]. Anti-QS molecules such as brominated furanones have the potential to 198	  
revert antibiotic tolerance of P. aeruginosa or E. coli persister cells [55,56]. Persisters 199	  
tolerance could also be reduced by exploiting their weaknesses related to their slow 200	  
metabolism, such as a high sensitivity to proteolysis induced by the acyldepsipeptide 201	  
ADEP4 that activates the ClpP protease in Gram-positive pathogens. ADEP4 is active in 202	  
combination with rifampicin in a neutropenic mouse biofilm model [57••]. Whereas the 203	  
efficacy of these anti-persister approaches remains to be further validated, on-going 204	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persister studies are likely to reveal other potential therapeutic strategies, such as the 205	  
modulation of bacterial cell death [58•]. 206	  
 207	  
 208	  
Future perspectives 209	  
 210	  
Much ado for almost nothing in clinic… Why? 211	  
The intense fundamental research on biofilms led to the emergence of numerous 212	  
promising antibiofilm approaches. However, despite these long-lasting efforts, one should 213	  
acknowledge that the translation of in vitro and in vivo data into clinical settings is slow and 214	  
somewhat disappointing. Beyond the simple explanation of the massive costs necessary 215	  
for drug development toward medical usage, one can identify potential reasons explaining 216	  
this delay. Not only preventive strategies are difficult to translate into the clinic, but non-217	  
biocidal preventive anti-adhesive or anti-virulence strategies face the diversity of bacterial 218	  
phenotypes and may only be active against a subpopulation of bacteria encountered in 219	  
clinical settings, therefore limiting their overall efficacy. Then, even if in vitro biofilm 220	  
susceptibility testing is a mandatory first step and much efforts have been made to develop 221	  
such in vitro testing [59], molecules identified in vitro should be validated using relevant in 222	  
vivo models for their antibiofilm activity but also absence of toxicity and pharmacokinetics. 223	  
 224	  
The limitation of biofilm models 225	  
Despite the diversity of both the in vitro and the in vivo models currently available to 226	  
identify or test antibiofilm molecules, in vitro models only partially reflect in vivo situations, 227	  
because in vitro biofilms are probably structurally different and respond differently as 228	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compared with in vivo biofilms [60••]. In particular, antibiotic tolerance in biofilms has been 229	  
obtained in vitro with starvation models [61•] but other stress factors could also play a role 230	  
in physiopathological conditions (flow, local pH, anoxia, inflammation…). At the present 231	  
time, the diversity of persister phenotypes is not known, possibly due to the diversity of the 232	  
in vitro conditions leading to persistence and the complexity of biofilm clinical situations. 233	  
Efforts should therefore be made to enrich in vitro models with flow conditions, type of 234	  
medium used, presence or absence of blood components or even specific eukaryotic cells 235	  
within the device. These issues should also apply for in vivo models. Beyond the question 236	  
of the relevance of using rodent models, some in vivo models may not properly reproduce 237	  
real clinical situations. One can, for example, wonder about the relevance of the rat agar 238	  
beads model to faithfully reproduce chronic infection in the lungs or subcutaneous model 239	  
of catheters that are not connected to the bloodstream. Furthermore, as for clinical trials, 240	  
rigorous statistical analysis and experimental set-up are mandatory in order to avoid any 241	  
false positive interpretation. One can however foresee that increasing use of new 242	  
guidelines for reporting animal research will also improve quality of experimental in vivo 243	  
models [62,63]. 244	  
 245	  
What could be the near future?	  246	  
Biofilm research will certainly benefit from the development of high throughput screenings 247	  
evaluating compounds in combination with antibiotics using models better mimicking in 248	  
vivo physiological conditions and new readouts benefiting from the increased knowledge 249	  
on biofilm related signaling, such as reporter genes for pathways related to persistence 250	  
(ppGpp, cyclic-di-GMP for Gram-negative bacteria, persisters metabolism). It is also 251	  
expected that new formulations based on polymer microparticles could also emerge and 252	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improve the use of otherwise topic compounds for local delivery at the site of biofilm 253	  
infection [64,65•]. To become more translational, biofilm research needs biomarkers and 254	  
more global analyses performed directly on biofilms in clinical settings, which are currently 255	  
essentially applied to in vitro or animal models. These omics analyses could provide new 256	  
and unexpected targets. Lastly, the increasing awareness of the polymicrobial nature of 257	  
biofilms should lead to the development of dedicated approaches to study bacteria-258	  
bacteria or bacteria-fungi interactions and their consequences on biofilm pathogenesis or 259	  
tolerance towards antibiotics [66]. 260	  261	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Table 1. Recent studies illustrating some promising non-pharmaceutical anti-biofilm strategies. This list is not comprehensive 
and is only meant to illustrate each approach. 
Mode of action In vitro In vivo References 
Early detection       
 
Detection of biofilm formation in 
a central venous catheter (CVC) 
using impedimetric biosensor 
Detection of S. epidermidis biofilm 
formation within the chamber of a CVC - [67] 
      
Vaccination       
 
Immunization against Biofilm 
Matrix Exoproteins from S. 
aureus 
- 
Reduction of S. aureus biofilm 
formation in a mesh biofilm model in 
mice 
[68] 
 
Passive protection with a 
monoclonal antibody against 
Enterococcus faecalis major pili 
protein EbpC 
Prevention of E. faecalis biofilm 
formation 
Significant passive protection against 
E. faecalis endocarditis in a rat model [69] 
     
Inhibition of microbial adhesion       
 
Modification of physical 
architecture of the surface 
(Sharklet micropattern) 
Reduction of E. coli, P. aeruginosa, A. 
baumannii and K. pneumonia adhesion - [70] 
     
Bio-inspired strategies       
 Quorum-sensing quencher    
 
New quorum-sensing quencher 
(F5, LasR inhibitor) from 
Pseudomonas sp 
Reduction of P. aeruginosa biofilm - [71] 
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 T7 engineered lytic phage producing a lactonase 
Inhibition of mixed P. aeruginosa and 
E. coli biofilm - [72] 
 Lytic enzymes from predators    
 Chimeric phage endolysin degrading peptidoglycan 
Disruption of S. aureus preformed 
biofilm 
Attenuation of S. aureus mediated 
endophtalmitis in mice [73] 
 Bdellovibrio bacteriovorus proteases and DNAse 
Prevention of S. aureus biofilm 
formation and disruption of S. aureus 
preformed biofilm 
- [74]  
 Other activity    
 Chitosan coupling with antibiotic or nitric oxide 
Disruption of and inhibition of Listeria, 
E. faecalis and S. aureus biofilm by 
chitosan-streptomycine conjugate ; 
disruption of P. aeruginosa biofilms by 
chitosan-NO conjugate 
- [75,76] 
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Figure 1. Biofilms: bacterial phenotypes and therapeutic targets 
Schematic drawing of the successive steps of biofilm formation and maturation highlighting the different bacterial phenotypes encountered 
and their susceptibility to antibiotics. The five major approaches to combat biofilms are represented with their impact on biofilm formation 
or integrity and their possible combination with antibiotics. 
 
